Hip Pain in 17-Year-Old Patient

The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and other areas in myelofibrosis.

Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.

Heath Skinner, MD, PhD, discussed the 4 focus areas of the 2026 Radiation Oncology Conference and what it takes to implement new radiation service lines.

The FDA has assigned a Prescription Drug User Fee Act date of March 31, 2027, for tabelecleucel in this indication.

Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.

Ralph V. Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration multiple myeloma care.

Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive non-muscle invasive bladder cancer.

The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.